Quest Diagnostics Announces Final Tender Offer Results
November 20 2009 - 8:30AM
PR Newswire (US)
MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Quest Diagnostics
Incorporated (the "Company") (NYSE:DGX), the world's leading
provider of diagnostic testing, information and services, announced
today the final results for its previously announced cash tender
offer (the "Tender Offer") to purchase any and all of its 5.125%
Senior Notes due 2010 and any and all of its 7.50% Senior Notes due
2011 (collectively, the "Notes"). Additional terms and conditions
of the Tender Offer are set forth in the offer to purchase dated
November 12, 2009 and the related letter of transmittal. The
settlement date for the Tender Offer will be today, November 20,
2009. The table below identifies the principal amount of each
series of Notes validly tendered and accepted for purchase by the
Company. Percentage of Principal Amount Title of Aggregate
Principal Amount Outstanding Series of Principal Amount Tendered
and Tendered CUSIP No. Securities Outstanding Accepted and Accepted
--------- ---------- ---------------- ----------------
---------------- 74834LAK6 5.125% $226,363,000 $60,829,000 26.87%
Senior Notes due 2010 74834LAE0 7.50% $248,637,000 $89,369,000
35.94% Senior Notes due 2011 The Company retained BofA Merrill
Lynch as Global Coordinator & Joint Lead Dealer Manager and
Morgan Stanley, RBS and Wells Fargo Securities as Joint Lead Dealer
Managers. Global Bondholder Services Corporation was retained to
serve as the Depositary and to serve as the Information Agent for
the Tender Offer. For additional information regarding the terms of
the Tender Offer, please contact: BofA Merrill Lynch at (888)
292-0070 (toll free) or (980) 388-4603 (collect). About Quest
Diagnostics Quest Diagnostics is the world's leading provider of
diagnostic testing, information and services that patients and
doctors need to make better healthcare decisions. The company
offers the broadest access to diagnostic testing services through
its network of laboratories and patient service centers, and
provides interpretive consultation through its extensive medical
and scientific staff. Quest Diagnostics is a pioneer in developing
innovative diagnostic tests and advanced healthcare information
technology solutions that help improve patient care. Additional
company information is available at
http://www.questdiagnostics.com/. The statements in this press
release which are not historical facts may be forward-looking
statements. Readers are cautioned not to place undue reliance on
forward-looking statements, which speak only as of the date that
they are made and which reflect management's current estimates,
projections, expectations or beliefs and which involve risks and
uncertainties that could cause actual results and outcomes to be
materially different. Risks and uncertainties that may affect the
future results of the company include, but are not limited to,
adverse results from pending or future government investigations,
lawsuits or private actions, the competitive environment, changes
in government regulations, changing relationships with customers,
payers, suppliers and strategic partners and other factors
discussed in "Business," "Risk Factors," "Cautionary Factors that
May Affect Future Results," "Legal Proceedings," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations," and "Quantitative and Qualitative Disclosures About
Market Risk" in the Company's 2008 Annual Report on Form 10-K and
"Management's Discussion and Analysis of Financial Condition and
Results of Operations," "Quantitative and Qualitative Disclosures
About Market Risk" and "Risk Factors" in the Company's 2009
Quarterly Reports on Form 10-Q and other items throughout the Form
10-K and the Company's 2009 Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. Media Contact: Kathleen Valentine,
Investors, +1-973-520-2900, or Wendy Bost, Media, +1-973-520-2800,
both for Quest Diagnostics Incorporated DATASOURCE: Quest
Diagnostics Incorporated CONTACT: Media Contact: Kathleen
Valentine, Investors, +1-973-520-2900, or Wendy Bost, Media,
+1-973-520-2800, both for Quest Diagnostics Incorporated Web Site:
http://www.questdiagnostics.com/
Copyright